Malformation syndromes associated with disorders of sex development

Nature Reviews Endocrinology

Volumn 10, Issue 8, 2014, Pages 476-487

  Hutson, John M ^a   Grover, Sonia R ^a   O'Connell, Michele ^a   Pennell, Samuel D ^b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL WALL DEFECT; ANORECTAL MALFORMATION; ATRX SYNDROME; CAUDAL REGRESSION SYNDROME; CHOLESTEROL METABOLISM; CHROMOSOME ABERRATION; CONGENITAL ADRENAL HYPOPLASIA; DELETION 4P SYNDROME; DENYS DRASH SYNDROME; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISORDER OF SEX DEVELOPMENT; DISORDERS OF STEROID METABOLISM; FACIOGENITAL DYSPLASIA; FRASER SYNDROME; FRASIER SYNDROME; GENE MUTATION; GENITAL SYSTEM; GONADAL DYSGENESIS; HERLYN WERNER WUNDERLICH SYNDROME; HUMAN; HYPOGONADISM; KALLMANN SYNDROME; KLINEFELTER SYNDROME; MALFORMATION SYNDROME; MULLERIAN DUCT SYNDROME; MULTIPLE MALFORMATION SYNDROME; NONHUMAN; NOONAN SYNDROME; OPITZ SYNDROME; PERINEUM DEFECT; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REVIEW; RIEGER SYNDROME; ROBINOW SYNDROME; ROKITANSKY SYNDROME; RUBINSTEIN SYNDROME; SEX DETERMINATION; SEX DIFFERENTIATION; SIRENOMELIA; SYNDROME CHARGE; TURNER SYNDROME; WAARDENBURG SYNDROME; WAGR SYNDROME; XY GONADAL DYSGENESIS;

ALPHA-THALASSEMIA; ANIMALS; CLEFT PALATE; DENYS-DRASH SYNDROME; DISORDERS OF SEX DEVELOPMENT; ESOPHAGUS; FEMALE; FRASIER SYNDROME; GENETIC DISEASES, X-LINKED; GENITALIA; GONADAL DYSGENESIS; GONADAL DYSGENESIS, 46,XY; HUMANS; HYPERTELORISM; HYPOGONADISM; HYPOSPADIAS; MALE; MENTAL RETARDATION, X-LINKED; TURNER SYNDROME; WAGR SYNDROME;

EID: 84904768430     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.83     Document Type: Review

References (149)

1. Hutson, J. M., Warne, G. L. & Grover, S. R. Disorders of Sex Development: An Integrated Approach to Management (Springer, 2012).
2. Low, Y., Deshpande, A. V. & Hutson J. M. Lethal comorbidity with genital anomaly in the infant. J. Pediatr. Urol. 2, 534-538 (2006).
3. Low, Y. & Hutson, J. M. Rules for clinical diagnosis in babies with ambiguous genitalia. J. Paediatr. Child Health 39, 406-413 (2003).
4. Wilhelm, D., Yang, J. X. & Thomas, P. Mammalian sex determination and gonad development. Curr. Top. Dev. Biol. 106, 89-121 (2013).
5. Pearlman, A. et al. Mutations in MAP3K1 cause 46, XY disorders of sex development and implicate a common signal transduction pathway in human testis determination. Am. J. Hum. Genet. 87, 898-904 (2010).
6. Baxter, R. M. & Vilain, E. Translational genetics for diagnosis of human disorders of sex development. Annu. Rev. Genomics Hum. Genet. 14, 371-392 (2013).
7. Biason-Lauber, A. et al. Ovaries and female phenotype in a girl with 46, XY karyotype and mutations in the CBX2 gene. Am. J. Hum. Genet. 84, 658-663 (2009).
8. Lin, L. et al. Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46, XY disorders of sex development with normal adrenal function. J. Clin. Endocrinol. Metab. 92, 991-999 (2007).
9. Kohler, B. & Achermann, J. C. Update-steroidogenic factor 1 (SF-1, NR5A1). Minerva Endocrinol. 35, 73-86 (2010).
10. Lourenço, D. et al. Loss-of-function mutation in GATA4 causes anomalies of human testicular development. Proc. Natl Acad. Sci. USA 108, 1597-1602 (2011).
11. White, S. et al. Copy number variation in patients with disorders of sex development due to 46, XY gonadal dysgenesis. PLoS ONE 6, e17793 (2011).
12. Umehara, F. et al. A novel mutation of desert hedgehog in a patient with 46, XY partial gonadal dysgenesis accompanied by minifascicular neuropathy. Am. J. Hum. Genet. 67, 1302-1305 (2000).
13. Tang, P. et al. Comparative analysis of the ATRX promoter and 5' regulatory region reveals conserved regulatory elements which are linked to roles in neurodevelopment, α-globin regulation and testicular function. BMC Res. Notes 4, 200 (2011).
14. Ogata, T., Wada, Y. & Fukami, M. MAMLD1 (CXorf6): a new gene for hypospadias. Sex Dev. 2, 244-250 (2008).
15. Puffenberger, E. G. et al. Mapping of sudden infant death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and identification of TSPYL loss of function. Proc. Natl Acad. Sci. USA 101, 11689-11694 (2004).
16. Gibbons, R. Alpha thalassaemia-mental retardation, X linked. Orphanet J. Rare Dis. 1, 15 (2006).
17. Ausio, J. et al. Syndromes of disordered chromatin remodeling. Clin. Genet. 64, 83-95 (2003).
18. Fischbach, B. V. et al. WAGR syndrome: a clinical review of 54 cases. Pediatrics 116, 984-988 (2005).
19. Breslow, N. E. et al. Renal failure in the Denys-Drash and Wilms' tumor-aniridia syndromes. Cancer Res. 60, 4030-4032 (2000).
20. Shapiro, O. et al. Mixed gonadal dysgenesis and Denys-Drash syndrome: urologists should screen for nephrotic syndrome. Can. J. Urol. 14, 3767-3769 (2007).
21. Chernin, G. et al. Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations. Clin. J. Am. Soc. Nephrol. 5, 1655-1662 (2010).
22. Gwin, K. et al. Expanding the clinical spectrum of Frasier syndrome. Pediatr. Dev. Pathol. 11, 122-127 (2008).
23. Nso Roca, A. P. et al. Evolutive study of children with diffuse mesangial sclerosis. Pediatr. Nephrol. 24, 1013-1019 (2009).
24. Breslow, N. E. et al. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J. Urol. 174, 1972-1975 (2005).
25. Auber, F. et al. Management of Wilms tumors in Drash and Frasier syndromes. Pediatr. Blood Cancer 52, 55-59 (2009).
26. Ariyaratana, S. & Loeb, D. M. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev. Mol. Med. 9, 1-17 (2007).
27. Slavotinek, A. M. Single gene disorders associated with congenital diaphragmatic hernia. Am. J. Med. Genet. C Semin. Med. Genet. 145C, 172-183 (2007).
28. Kitsiou-Tzeli, S. et al. Sertoli cell tumor and gonadoblastoma in an untreated 29-year-old 46, XY phenotypic male with Frasier syndrome carrying a WT1 IVS9+4C>T mutation. Hormones (Athens) 11, 361-367 (2012).
29. Robin, N. H. et al. Opitz syndrome is genetically heterogeneous, with one locus on Xp22, and a second locus on 22q11.2. Nat. Genet. 11, 459-461 (1995).
30. Migliore, C. et al. Complex rearrangement of the exon 6 genomic region among Opitz G/BBB syndrome MID1 alterations. Eur. J. Med. Genet. 56, 404-410 (2013).
31. Linden, M. G. Bender, B. G. & Robinson, A. Intrauterine diagnosis of sex chromosome aneuploidy. Obstet. Gynecol. 87, 468-475 (1996).
32. Zhong, Q. & Layman, L. C. Genetic considerations in the patient with Turner syndrome-45, X with or without mosaicism. Fertil. Steril. 98, 775-779 (2012).
33. Sybert, V. P. Adult height in Turner syndrome with and without androgen therapy. J. Pediatr. 104, 365-369 (1984).
34. Bondy, C. et al. Bicuspid aortic valve and aortic coarctation are linked to deletion of the X chromosome short arm in Turner syndrome. J. Med. Genet. 50, 662-665 (2013).
35. Trolle, C. et al. Long QT interval in Turner syndrome-A high prevalence of LQTS gene mutations. PLoS ONE 8, e69614 (2013).
36. Cramer, J. W. et al. The spectrum of congenital heart disease and outcomes after surgical repair among children with Turner syndrome: a singlecenter review. Pediatr. Cardiol. 35, 253-260 (2014).
37. Bergamaschi, R. et al. Hearing loss in Turner syndrome: results of a multicentric study. J. Endocrinol. Invest. 31, 779-783 (2008).
38. Morimoto, N. et al. Hearing loss in Turner syndrome. J. Pediatr. 149, 697-701 (2006).
39. Mazzocco, M. M. et al. Social functioning among girls with fragile X or Turner syndrome and their sisters. J. Autism Dev. Disord. 28, 509-517 (1998).
40. Hewitt, J. K. et al. Fertility in Turner syndrome. Clin. Endocrinol. (Oxf.) 79, 606-614 (2013).
41. Goldacre, M. J. & Seminog, O. O. Turner syndrome and autoimmune diseases: record-linkage study. Arch. Dis. Child. 99, 71-73 (2014).
42. Gonzalez, L. & Witchel, S. F. The patient with Turner syndrome: puberty and medical management concerns. Fertil. Steril. 98, 780-786 (2013).
43. Capito, C. et al. 46, XY pure gonadal dysgenesis: clinical presentations and management of the tumor risk. J. Pediatr. Urol. 7, 72-75 (2011).
44. Fallat, M. E. & Donahoe, P. K. Intersex genetic anomalies with malignant potential. Curr. Opin. Pediatr. 18, 305-311 (2006).
45. Hersmus, R. et al. New insights into type II germ cell tumor pathogenesis based on studies of patients with various forms of disorders of sex development (DSD). Mol. Cell Endocrinol. 291, 1-10 (2008).
46. Hersmus, R. et al. FOXL2 and SOX9 as parameters of female and male gonadal differentiation in patients with various forms of disorders of sex development (DSD). J. Pathol. 215, 31-38 (2008).
47. Michala, L. et al. Swyer syndrome: presentation and outcomes. BJOG 115, 737-741 (2008).
48. Zielinska, D., Zajaczek, S. & Rzepka-Gorska, I. Tumors of dysgenetic gonads in Swyer syndrome. J. Pediatr. Surg. 42, 1721-1724 (2007).
49. Groth, K. A. et al. Clinical review: Klinefelter syndrome-A clinical update. J. Clin. Endocrinol. Metab. 98, 20-30 (2013).
50. Lee, Y. S. et al. Genital anomalies in Klinefelter's syndrome. Horm. Res. 68, 150-155 (2007).
51. Nahata, L. et al. Klinefelter syndrome: are we missing opportunities for early detection? Clin. Pediatr. (Phila.) 52, 936-941 (2013).
52. Rives, N. et al. The feasibility of fertility preservation in adolescents with Klinefelter syndrome. Hum. Reprod. 28, 1468-1479 (2013).
53. Aksglaede, L. & Juul, A. Testicular function and fertility in men with Klinefelter syndrome: a review. Eur. J. Endocrinol. 168, R67-R76 (2013).
54. Aksglaede, L. et al. 47, XXY Klinefelter syndrome: clinical characteristics and age-specific recommendations for medical management. Am. J. Med. Genet. C Semin. Med. Genet. 163C, 55-63 (2013).
55. Rauen, K. A. The RASopathies. Annu. Rev. Genomics Hum. Genet. 14, 355-369 (2013).
56. Roberts, A. E. et al. Noonan syndrome. Lancet 381, 333-342 (2013).
57. Adviento, B. et al. Autism traits in the RASopathies. J. Med. Genet. 51, 10-20 (2014).
58. Aoki, Y. et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am. J. Hum. Genet. 93, 173-180 (2013).
59. Lewkowitz-Shpuntoff, H. M. et al. Olfactory phenotypic spectrum in idiopathic hypogonadotropic hypogonadism: pathophysiological and genetic implications. J. Clin. Endocrinol. Metab. 97, E136-E144 (2012).
60. Miraoui, H. et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am. J. Hum. Genet. 92, 725-743 (2013).
61. Pitteloud, N. et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc. Natl Acad. Sci. USA 104, 17447-17452 (2007).
62. Pingault, V. et al. Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness. Am. J. Hum. Genet. 92, 707-724 (2013).
63. Dode, C. & Rondard, P. PROK2/PROKR2 signaling and Kallmann syndrome. Front. Endocrinol. (Lausanne) 4, 19 (2013).
64. Costa-Barbosa, F. A. et al. Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. J. Clin. Endocrinol. Metab. 98, E943-E953 (2013).
65. Bergman, J. E. et al. The results of CHD7 analysis in clinically well-characterized patients with Kallmann syndrome. J. Clin. Endocrinol. Metab. 97, E858-E862 (2012).
66. Corsten-Janssen, N. et al. The cardiac phenotype in patients with a CHD7 mutation. Circ. Cardiovasc. Genet. 6, 248-254 (2013).
67. White, D. R. et al. Aspiration in children with CHARGE syndrome. Int. J. Pediatr. Otorhinolaryngol. 69, 1205-1209 (2005).
68. Valeri, C., Schteingart, H. F. & Rey, R. A. The prepubertal testis: biomarkers and functions. Curr. Opin. Endocrinol. Diabetes Obes. 20, 224-233 (2013).
69. Cassidy, S. B. et al. Prader-Willi syndrome. Genet. Med. 14, 10-26 (2012).
70. Bridges, N. What is the value of growth hormone therapy in Prader Willi syndrome? Arch. Dis. Child. 99, 166-170 (2014).
71. Emerick, J. E. & Vogt, K. S. Endocrine manifestations and management of Prader-Willi syndrome. Int. J. Pediatr. Endocrinol. 2013, 14 (2013).
72. Horsthemke, B. & Wagstaff, J. Mechanisms of imprinting of the Prader-Willi/Angelman region. Am. J. Med. Genet. A 146A, 2041-2052 (2008).
73. Miller, J. L. et al. Intracranial abnormalities detected by three-dimensional magnetic resonance imaging in Prader-Willi syndrome. Am. J. Med. Genet. A 143, 476-483 (2007).
74. Farooqi, I. S. et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N. Engl. J. Med. 356, 237-247 (2007).
75. Ogura, K. et al. Regional cerebral blood flow and abnormal eating behavior in Prader-Willi syndrome. Brain Dev. 35, 427-434 (2013).
76. Gilboa, T. & Gross-Tsur, V. Epilepsy in Prader-Willi syndrome: experience of a national referral centre. Dev. Med. Child. Neurol. 55, 857-861 (2013).
77. Barbaro, M. et al. Multiplex ligation-dependent probe amplification analysis of the NR0B1(DAX1) locus enables explanation of phenotypic differences in patients with X-linked congenital adrenal hypoplasia. Horm. Res. Paediatr. 77, 100-107 (2012).
78. Aminzadeh, M. et al. Rarer syndromes characterized by hypogonadotropic hypogonadism. Front. Horm. Res. 39, 154-167 (2010).
79. Landau, Z. et al. Clinical and genetic heterogeneity of congenital adrenal hypoplasia due to NR0B1 gene mutations. Clin. Endocrinol. (Oxf.) 72, 448-454 (2010).
80. Li, N. et al. Seven novel DAX1 mutations with loss of function identified in Chinese patients with congenital adrenal hypoplasia. J. Clin. Endocrinol. Metab. 95, E104-E111 (2010).
81. Bartsch, O. et al. Evidence for a new contiguous gene syndrome, the chromosome 16p13.3 deletion syndrome alias severe Rubinstein-Taybi syndrome. Hum. Genet. 120, 179-186 (2006).
82. van Belzen, M. et al. Rubinstein-Taybi syndrome (CREBBP, EP300). Eur. J. Hum. Genet. 19, 118-120 (2010).
83. Schorry, E. K. et al. Genotype-phenotype correlations in Rubinstein-Taybi syndrome. Am. J. Med. Genet. A 146A, 2512-2519 (2008).
84. Stevens, C. A., Pouncey, J. & Knowles, D. Adults with Rubinstein-Taybi syndrome. Am. J. Med. Genet. A 155A, 1680-1684 (2011).
85. Miller, R. W. & Rubinstein, J. H. Tumors in Rubinstein-Taybi syndrome. Am. J. Med. Genet. 56, 112-115 (1995).
86. Chang, T. C. et al. Axenfeld-Rieger syndrome: new perspectives. Br. J. Ophthalmol. 96, 318-322 (2011).
87. Tumer, Z. & Bach-Holm, D. Axenfeld-Rieger syndrome and spectrum of PITX2 and FOXC1 mutations. Eur. J. Hum. Genet. 17, 1527-1539 (2009).
88. Battaglia, A. 1p36 Deletion Syndrome [online], http://www.ncbi.nlm.nih. gov/books/NBK1191/(2013).
89. Barisic, I. et al. Fraser syndrome: epidemiological study in a European population. Am. J. Med. Genet. A 161A, 1012-1018 (2013).
90. van Haelst, M. M. Scambler, P. J. & Hennekam, R. C. Fraser syndrome: a clinical study of 59 cases and evaluation of diagnostic criteria. Am. J. Med. Genet. A 143A, 3194-3203 (2007).
91. Vogel, M. J. et al. Mutations in GRIP1 cause Fraser syndrome. J. Med. Genet. 49, 303-306 (2012).
92. Porter, F. D. Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur. J. Hum. Genet. 16, 535-541 (2008).
93. Porter, F. D. & Herman, G. E. Malformation syndromes caused by disorders of cholesterol synthesis. J. Lipid Res. 52, 6-34 (2011).
94. Herman, G. E. & Kratz, L. Disorders of sterol synthesis: beyond Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 160C, 301-321 (2012).
95. Nowaczyk, M. J. & Irons, M. B. Smith-Lemli-Opitz syndrome: phenotype, natural history, and epidemiology. Am. J. Med. Genet. C Semin. Med. Genet. 160C, 250-262 (2012).
96. Chan, Y. M. et al. Effects of dietary cholesterol and simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome. Pediatr. Res. 65, 681-685 (2009).
97. DeBarber, A. E. et al. Smith-Lemli-Opitz syndrome. Expert Rev. Mol. Med. 13, e24 (2011).
98. Scott, R. R. & Miller, W. L. Genetic and clinical features of p450 oxidoreductase deficiency. Horm. Res. 69, 266-275 (2008).
99. Kanungo, S. et al. Sterol metabolism disorders and neurodevelopment-an update. Dev. Disabil. Res. Rev. 17, 197-210 (2013).
100. Fluck, C. E. et al. P450 oxidoreductase deficiency-A new form of congenital adrenal hyperplasia. Endocr. Dev. 13, 67-81 (2008).
101. Hutson, J. M. et al. The regulation of testicular descent and the effects of cryptorchidism. Endocr. Rev. 34, 725-752 (2013).
102. Mazzeu, J. F. et al. Chromosome abnormalities in two patients with features of autosomal dominant Robinow syndrome. Am. J. Med. Genet. A 143A, 1790-1795 (2007).
103. Nouraei, S. M. et al. Aarskog syndrome with aortic root dilatation and sub-valvular aortic stenosis: surgical management. Interact. Cardiovasc. Thorac. Surg. 4, 47-48 (2005).
104. Orrico, A. et al. Aarskog-Scott syndrome: clinical update and report of nine novel mutations of the FGD1 gene. Am. J. Med. Genet. A 152A, 313-318 (2010).
105. Hutson, J. M. Undescended testis: the underlying mechanisms and the effects on germ cells that cause infertility and cancer. J. Pediatr. Surg. 48, 903-908.
106. Josso, N., Rey, R. & Picard, J. Y. Testicular anti-Mullerian hormone: clinical applications in DSD. Semin. Reprod. Med. 30, 364-373 (2012).
107. Nishi, M. Y. et al. Analysis of anti-Mullerian hormone (AMH) and its receptor (AMHR2) genes in patients with persistent Mullerian duct syndrome. Arq. Bras. Endocrinol. Metabol. 56, 473-478 (2012).
108. Salehi, P. et al. Persistent Mullerian duct syndrome: 8 new cases in Southern California and a review of the literature. Pediatr. Endocrinol. Rev. 10, 227-233 (2012).
109. Hutson, J. M., Chow, C. W. & Ng, W.-D. Persistent Mullerian duct syndrome with transverse testicular ectopia. Pediatr. Surg. Int. 2, 191-194 (1987).
110. Colacurci, N. et al. Laparoscopic hysterectomy in a case of male pseudohermaphroditism with persistent Mullerian duct derivatives. Hum. Reprod. 12, 272-274 (1997).
111. Hutson, J. M. & Baker, M. L. A hypothesis to explain abnormal gonadal descent in persistent Mullerian duct syndrome. Pediatr. Surg. Int. 9, 542-543 (1994).
112. Josso, N. et al. The persistent Mullerian duct syndrome: a rare cause of cryptorchidism. Eur. J. Pediatr. 152, S76-S78 (1993).
113. Imbeaud, S. et al. Testicular degeneration in three patients with the persistent Mullerian duct syndrome. Eur. J. Pediatr. 154, 187-190 (1995).
114. Josso, N. et al. Anti-Mullerian hormone: the Jost factor. Recent Prog. Horm. Res. 48, 1-59 (1993).
115. Tong, S. Y. C., Hutson, J. M. & Watts, L. M. Does testosterone diffuse down the Wolffian duct during sexual differentiation? J. Urol. 155, 2057-2059 (1996).
116. Hannema, S. E. & Hughes, I. A. Regulation of Wolffian duct development. Horm. Res. 67, 142-151 (2007).
117. Singh, R. et al. Physical deformities relevant to male infertility. Nat. Rev. Urol. 9, 156-174 (2012).
118. Yu, J. et al. CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. Hum. Reprod. 27, 25-35 (2012).
119. Marcorelles, P. et al. Cystic fibrosis transmembrane conductance regulator protein expression in the male excretory duct system during development. Hum. Pathol. 43, 390-397 (2012).
120. Bombieri, C. et al. Recommendations for the classification of diseases as CFTR-related disorders. J. Cyst. Fibros. 10 (Suppl. 2), S86-S102 (2011).
121. Radpour, R. et al. Genetic investigations of CFTR mutations in congenital absence of vas deferens, uterus, and vagina as a cause of infertility. J. Androl. 29, 506-513 (2008).
122. Claustres, M. Molecular pathology of the CFTR locus in male infertility. Reprod. Biomed. Online 10, 14-41 (2005).
123. nd edn (Martin Dunitz, 2002).
124. Pizzo, A. et al. Mayer-Rokitansky-Kuster-Hauser syndrome: embryology, genetics and clinical and surgical treatment. ISRN Obstet. Gynecol. 2013, 628717 (2013).
125. Guerrier, D. et al. The Mayer-Rokitansky-Kuster-Hauser syndrome (congenital absence of uterus and vagina)-phenotypic manifestations and genetic approaches. J. Negat. Results Biomed. 5, 1 (2006).
126. Ekici, A. B. et al. HOXA10 and HOXA13 sequence variations in human female genital malformations including congenital absence of the uterus and vagina. Gene 518, 267-272 (2013).
127. Wottgen, M. et al. Higher incidence of linked malformations in siblings of Mayer-Rokitansky-Kuster-Hauser-syndrome patients. Hum. Reprod. 23, 1226-1231 (2008).
128. Oppelt, P. G. et al. Malformations in a cohort of 284 women with Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH). Reprod. Biol. Endocrinol. 10, 57 (2012).
129. Kimberley, N. et al. Vaginal agenesis, the hymen, and associated anomalies. J. Pediatr. Adolesc. Gynecol. 25, 54-58 (2012).
130. Aveiro, A. C. et al. Herlyn-Werner-Wunderlich syndrome: a rare cause of pelvic pain in adolescent girls. BMJ Case Rep. 2011, bcr0420114147 (2011).
131. Fedele, L. et al. Double uterus with obstructed hemivagina and ipsilateral renal agenesis: pelvic anatomic variants in 87 cases. Hum. Reprod. 28, 1580-1583 (2013).
132. Tong, J., Zhu, L. & Lang, J. Clinical characteristics of 70 patients with Herlyn-Werner-Wunderlich syndrome. Int. J. Gynaecol. Obstet. 121, 173-175 (2013).
133. Hassett, S. Smith, G. H. & Holland, A. J. Prune belly syndrome. Pediatr. Surg. Int 28, 219-228 (2012).
134. Zugor, V., Schott, G. E. & Labanaris, A. P. The Prune belly syndrome: urological aspects and long-term outcomes of a rare disease. Pediatr. Rep. 4, e20 (2012).
135. Hutson, J. M. & Beasley, S. W. Aetiology of the prune belly syndrome. Aust. Paediatr. J. 23, 309-310 (1987).
136. McMullin, N. D. & Hutson, J. M. Female pseudohermaphroditism in children with cloacal anomalies. Pediatr. Surg. Int. 6, 56-59 (1991).
137. Stec, A. A., Baradaran, N. & Gearhart, J. P. Congenital renal anomalies in patients with classic bladder exstrophy. Urology 79, 207-209 (2012).
138. Wilkins, S. et al. Insertion/deletion polymorphisms in the DeltaNp63 promoter are a risk factor for bladder exstrophy epispadias complex. PLoS Genet. 8, e1003070 (2012).
139. Mahfuz, I. et al. New insights into the pathogenesis of bladder exstrophy-epispadias complex. J. Pediatr. Urol. 9, 996-1005 (2013).
140. Srinivasan, J., McDougall, P. & Hutson, J. M. When is 'intersex' not intersex? A case of penile agenesis demonstrates how to distinguish non-endocrine disorders in neonates with genital anomaly. J. Paediatr. Child. Health 39, 629-631 (2003).
141. Rattan, K. N. et al. Aphallia: experience with 3 cases. J. Pediatr. Surg. 45, E13-E16 (2010).
142. Bartsch, O. et al. Evidence for a critical region for penoscrotal inversion, hypospadias, and mperforate anus within chromosomal region 13q32.2q34. Am. J. Med. Genet 65, 218-221 (1996).
143. Quelin, C. et al. Twelve new patients with 13q deletion syndrome: genotype-phenotype analyses in progress. Eur. J. Med. Genet. 52, 41-46 (2009).
144. Andresen, J. H. et al. 13q33.2 deletion: a rare cause of ambiguous genitalia in a male newborn with growth restriction. Acta Paediatr. 99, 784-786 (2010).
145. Brown, S. et al. Preliminary definition of a "critical region" of chromosome 13 in q32: report of 14 cases with 13q deletions and review of the iterature. Am. J. Med. Genet. 45, 52-59 (1993).
146. Hutson, J. M. & Beasley, S. W. Why testicular descent may be impaired in cloacal exstrophy. Pediatr. Surg. Int. 4, 122-123 (1989).
147. Martucciello, G. in Anorectal Malformations in Children (eds Holschneider, A. M. & Hutson, J. M) 17-30 (Springer, 2006).
148. Stanton, M. P., Penington, E. C. & Hutson, J. M. A surviving infant with sirenomelia (Mermaid syndrome) associated with absent bladder. J. Pediatr. Surg. 38, 1266-1268 (2003).
149. Orioli, I. M. et al. Sirenomelia: an epidemiologic study in a large dataset from the International Clearinghouse of Birth Defects Surveillance and Research, and literature review. Am. J. Med. Genet. C Semin. Med. Genet. 157C, 358-373 (2011).